血清白细胞介素预测鼻咽癌免疫治疗疗效的前瞻性观察研究
该前瞻性研究纳入80例复发转移性鼻咽癌患者,动态检测血清IL-8和IL-6水平,分析其与抗PD-1/PD-L1抑制剂疗效的相关性。结果显示血清IL-8早期下降与疗效及生存显著相关,IL-6变化亦与疗效相关,两者可能成为预测免疫治疗疗效的生物标志物。
要点
- 有反应者最佳疗效时血清IL-8较基线显著降低,进展时显著升高。
- 血清IL-8早期变化百分比以-8.85%为界,AUC为0.913,灵敏度87.9%,特异度80.9%。
- IL-8早期下降≥8.85%组24个月累积生存率显著更高(85.1% vs 70.2%)。
核心结论
- 血清IL-8和IL-6水平变化与复发转移性鼻咽癌患者抗PD-1/PD-L1抑制剂疗效相关,可能成为有效且易评估的预测生物标志物。
- 血清IL-8早期下降(第1次给药后2~4周)与抗PD-1/PD-L1抑制剂疗效正相关。
研究设计与样本
- 前瞻性观察研究,纳入2022年1月至2024年12月华东医院80例复发转移性鼻咽癌患者,中位年龄62岁,均完成随访。
- 在基线、开始治疗后2~4周及每次随访时采集空腹外周血3 ml检测IL-8和IL-6水平。
主要发现
- 有反应者最佳疗效时中位血清IL-8为11.6 pg/ml(9.4,32.6 pg/ml),显著低于基线34.6 pg/ml(26.9,65.2 pg/ml),P<0.001;进展时升至79.0 pg/ml(44.55,107.7 pg/ml),P<0.001。
- 无反应者进展时中位血清IL-8为80.95 pg/ml(68.45,117.25 pg/ml),显著高于基线30.5 pg/ml(24.6,77.5 pg/ml),P<0.001。
- 血清IL-8早期变化百分比:有反应者-38.6%(-47.2%,-11.8%),无反应者44.5%(3.5%,59.8%),P<0.001。
- 有反应者进展时血清IL-6为11.4 pg/ml(4.7,25.3 pg/ml),显著高于最佳疗效时4.3 pg/ml(2.6,8.8 pg/ml),P<0.001;无反应者进展时15.9 pg/ml(7.3,23.3 pg/ml)显著高于基线7.9 pg/ml(4.5,17.2 pg/ml),P=0.030。
- 血清IL-6早期变化与疗效无关:有反应者-0.12%(-0.39%,0.27%),无反应者0.05%(-0.13%,0.20%),P=0.059。
关键数值与推荐
- 以基线至开始治疗后2~4周血清IL-8变化百分比-8.85%为临界值,AUC为0.913(95% CI:0.853~0.973,P<0.001),特异度80.9%(95% CI:66.7%~90.9%),灵敏度87.9%(95% CI:71.8%~96.6%)。
- 按IL-8早期变化比例分组:<-8.85%组死亡4例,≥-8.85%组死亡10例;24个月累积生存率分别为85.1%和70.2%(P=0.025)。
- ≥-8.85%组死亡风险是<-8.85%组的3.392倍(HR=3.392,95% CI:1.175~9.789)。
- 疗效评估采用RECIST 1.1版,完全缓解、部分缓解和疾病稳定定义为有反应者,疾病进展定义为无反应者。
临床怎么用
- 对复发转移性鼻咽癌患者接受抗PD-1/PD-L1抑制剂治疗时,可在基线及首次给药后2~4周检测血清IL-8,早期下降幅度可辅助预测疗效。
- IL-8早期变化百分比<-8.85%提示疗效和生存获益可能更好,≥-8.85%提示死亡风险较高,可考虑加强监测或调整治疗策略。
- 血清IL-6动态变化亦可辅助评估疾病进展,但早期变化不宜单独用于疗效预测。
局限性
- 单中心前瞻性观察研究,样本量80例,结果需多中心大样本验证。
- 原文未报告IL-8和IL-6预测疗效的其他混杂因素校正分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To explore the correlation between the changes in serum interleukin-8 (IL-8) and interleukin-6 (IL-6) levels and the efficacy of anti-programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors in patients with recurrent and metastatic nasopharyngeal carcinoma. Trying to identify predictive indicators for the efficacy of anti-PD-1/PD-L1 inhibitors in these patients. Methods: A prospective analysis was conducted on the clinical and laboratory data of 80 patients diagnosed with recurrent and metastatic nasopharyngeal carcinoma at Huadong Hospital from January 2022 to December 2024. Fasting peripheral blood (3 ml) was collected from patients at baseline, 2-4 weeks after the start of treatment, and at each follow-up visit to measure IL-8 and IL-6 levels, and the correlation between these levels and the efficacy of anti-PD-1/PD-L1 inhibitors was analyzed. Results: The median age of the patients was 62 years old, and 80 cases completed the follow-up. According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), patients with best responses of complete response, partial response, and stable disease were defined as responders; those with best responses of progressive disease were defined as non-responders. In responders, the median serum IL-8 level at best response (BR) was significantly lower than that at baseline (BL) [BL: 34.6(26.9, 65.2) pg/ml, BR: 11.6(9.4, 32.6) pg/ml; P<0.001], and significantly increased at progressive disease (PD)[BR: 11.6(9.4, 32.6) pg/ml, PD: 79.0(44.55, 107.7) pg/ml, P<0.001]. In non-responders, the median serum IL-8 level at PD was significantly higher than that at BL[BL: 30.5(24.6, 77.5) pg/ml, PD: 80.95(68.45, 117.25) pg/ml; P<0.001]. The early changes in serum IL-8 levels (2-4 weeks after the first dose) were associated with the efficacy of anti-PD-1/PD-L1 inhibitors [responders: -38.6%(-47.2%, -11.8%); non-responders: 44.5%(3.5%, 59.8%), P<0.001]. With a cut-off value of -8.85% for the percentage change in serum IL-8 levels from BL to 2-4 weeks, the area under the curve (AUC) was 0.913 (95% CI: 0.853-0.973; P<0.001), the specificity was 80.9% (95% CI: 66.7%-90.9%), and the sensitivity was 87.9% (95% CI: 71.8%-96.6%). Patients were divided into two groups based on the early change ratio of IL-8:<-8.85% change group and ≥-8.85% change group. There were 4 deaths in the <-8.85% change group and 10 deaths in the ≥-8.85% change group. The 24-month cumulative survival rate in the -8.85% change group was significantly higher than that in the ≥-8.85% change group (85.1% vs. 70.2%, P=0.025). The risk of death in the ≥-8.85% change group was 3.392 times higher than that of the < -8.85% change group(HR=3.392 ,95% CI: 1.175-9.789). In responders, the serum IL-6 level at PD was significantly higher than that at BR[BR: 4.3(2.6,8.8) pg/ml, PD: 11.4(4.7,25.3) pg/ml, P<0.001]. In non-responders, the serum IL-6 level at PD was significantly higher than that at BL [BL: 7.9(4.5,17.2) pg/ml, PD: 15.9(7.3,23.3) pg/ml, P=0.030]. The early changes in serum IL-6 levels were not associated with the efficacy of anti-PD-1/PD-L1 inhibitors[responders: -0.12%(-0.39%, 0.27%); non-responders: 0.05%(-0.13%, 0.20%), P=0.059]. Conclusions: The changes in serum IL-8 and IL-6 levels are associated with the efficacy of anti-PD-1/PD-L1 inhibitors in patients, which may be effective and easily assessable biomarkers for predicting the efficacy of anti-PD-1/PD-L1 inhibitors in patients with recurrent and metastatic nasopharyngeal carcinoma. An early decline in serum IL-8 levels (2-4 weeks after the first administration) is positively correlated with the efficacy of anti-PD-1/PD-L1 inhibitors. 目的: 探讨复发、转移性鼻咽癌患者血清白细胞介素-8(IL-8)和IL-6水平变化与程序性死亡受体1(PD-1)/程序性死亡受体配体1(PD-L1)抑制剂疗效之间的相关性。 方法: 前瞻性收集2022年1月至2024年12月期间在华东医院诊断为复发、转移性鼻咽癌患者(80例)的临床和实验室资料,在基线、开始治疗后2~4周和每次随访时收集患者空腹外周血(3 ml)检测IL-8、IL-6水平,并对患者PD-1/PD-L1抑制剂疗效进行相关性分析。 结果: 80例患者中位年龄62岁,均完成随访。在有反应者中(完全缓解、部分缓解和疾病稳定),最佳疗效时的中位血清IL-8水平[11.6 pg/ml(9.4,32.6 pg/ml)]与基线时[34.6 pg/ml(26.9,65.2 pg/ml)]相比显著降低(P<0.001),疾病进展(PD)时显著增加[最佳疗效时:11.6 pg/ml(9.4,32.6 pg/ml),PD:79.0 pg/ml(44.55,107.7 pg/ml),P<0.001]。在无反应者中(PD),PD时的中位血清IL-8水平[80.95 pg/ml(68.45,117.25 pg/ml)]与基线时[30.5 pg/ml(24.6,77.5 pg/ml)]相比显著升高(P<0.001)。血清IL-8水平的早期变化(第1次给药后2~4周)与PD-1/PD-L1抑制剂的疗效相关[有反应者:-38.6%(-47.2%,-11.8%);无反应者:44.5%(3.5%,59.8%),P<0.001]。以基线时和开始治疗后2~4周血清IL-8水平变化百分比的临界值-8.85%为界,曲线下面积为0.913(95% CI:0.853~0.973,P<0.001),特异度为80.9%(95% CI:66.7%~90.9%),灵敏度为87.9%(95% CI:71.8%~96.6%)。根据患者IL-8早期变化比例分为2组:<-8.85%变化组和≥8.85%变化组。<-8.85%变化组有4例死亡,≥-8.85%变化组有10例死亡。<-8.85%变化组24个月累积生存率(85.1%)显著高于≥-8.85%变化组(70.2%,P=0.025)。≥-8.85%变化组的死亡风险是<-8.85%变化组的3.392倍(HR=3.392,95% CI:1.175~9.789)。在有反应者中,与最佳疗效时相比,PD时的血清IL-6水平显著增加[最佳疗效时:4.3 pg/ml(2.6,8.8 pg/ml);PD:11.4 pg/ml(4.7,25.3 pg/ml),P<0.001]。在无反应者中,患者PD时的血清IL-6水平与基线相比显著升高[基线:7.9 pg/ml(4.5,17.2 pg/ml),PD:15.9 pg/ml(7.3,23.3 pg/ml),P=0.030]。血清IL-6水平的早期变化与PD-1/PD-L1抑制剂的疗效无关[有反应者:-0.12%(-0.39%,0.27%);无反应者:0.05%(-0.13%,0.20%),P=0.059]。 结论: 血清IL-8和IL-6水平的变化与PD-1/PD-L1抑制剂治疗的疗效相关。血清IL-8和IL-6可能是复发、转移性鼻咽癌患者对PD-1/PD-L1抑制剂疗效的有效且易于评估的生物预测标志物。血清IL-8水平的早期下降(第1次给药后2~4周)与PD-1/PD-L1抑制剂的疗效有关。.
引用
- Chen JY, Zhao T, Zhuang WJ, et al. [Serum interleukin predicts the efficacy of immunotherapy for nasopharyngeal carcinoma: a prospective observational study]. Zhonghua Zhong Liu Za Zhi. 2025. PMID: 41443740. doi:10.3760/cma.j.cn112152-20250412-00161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。